In a new study published in Molecular Genetics and Metabolism, researchers evaluated the use of goal attainment scaling (GAS) to assess treatment effectiveness in primary mitochondrial diseases (PMD), a group of rare genetic disorders that includes thymidine kinase 2 deficiency (TK2d).
Because these diseases are highly variable and can affect multiple organs and body systems, it can be difficult to measure treatment benefits in clinical trials.
GAS is a method that allows patients to set personalized goals at the start of a trial and then measure how well those goals are achieved over time. This approach is designed to capture changes that matter most to patients in their daily lives. Each goal is scored on a predefined scale ranging from outcomes that fall well below expectations to outcomes that exceed expectations.
For the new study, researchers analyzed a randomized controlled trial to investigate whether GAS could demonstrate construct validity, meaning that the measure accurately reflects meaningful clinical changes.
Learn more about TK2d treatment and care
The findings suggest that individualized goals can help capture treatment-related changes that might not be detected by standard clinical measures alone. Because each person’s goals are tailored to their specific symptoms or limitations, the method may provide a more flexible way to assess improvement in a condition where experiences differ widely among patients.
At the same time, the study highlighted several challenges. Developing appropriate goals requires careful planning to ensure that they are relevant to the treatment being studied. Consistency in how progress is evaluated is also important to reduce bias and maintain reliability across participants and researchers.
Overall, the study authors concluded that goal attainment scaling may serve as a useful additional outcome measure in clinical trials for primary mitochondrial disease, particularly when traditional tools cannot fully reflect the diverse ways the disease affects patients.
“Although exploratory, these findings suggest GAS may capture patient-relevant change in individuals with PMD,” the researchers conclude. “To realize its potential, standardized methodology and further validation are essential for its use as a robust outcome measure in future PMD trials.”
Sign up here to get the latest news, perspectives, and information about TK2d sent directly to your inbox. Registration is free and only takes a minute.